Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
* Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologies
* Reinforces Antharis' and Lonza's position at the forefront of dual-payload ADC development amid growing industry adoption of multi-warhead strategies
BASEL, Switzerland